APR 07, 2022 3:00 PM CEST

RET aberrations and EGFR exon 20 insertions testing in the complex NSCLC biomarker landscape

C.E. Credits: P.A.C.E. CE Florida CE


In this presentation the speaker will discuss latest developments in NSCLC precision therapy and biomarker landscape, and importance of NGS in NSCLC biomarker testing.

He will review the NSCLC biomarkers and targeted treatment landscape and current  the guidelines for NSCLC biomarker testing. A special focus will be on RET fusions and EGFR exon 20 insertions as some of the latest biomarkers becoming subject to routine testing. In light of all the discussed he will argue it is time to implement NGS as front-line biomarker testing technology in NSCLC.

Show Resources
Show Resources